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Purpose: Plasminogen kringle 5 (K5) is a potent angiogenic inhibitor and specifically binds to the voltage-dependent
anion channel believed to function as the K5 receptor (K5R). To investigate the role of K5R in diabetic retinopathy, the
present study measured the expression levels of K5R in the retina of diabetic retinopathy models. In cultured retinal Müller
cells, K5 inhibited vascular endothelial growth factor (VEGF) expression as shown with enzyme-linked immunosorbent
assay and western blot analysis, suggesting that K5 has a direct effect on Müller cells.
Methods: To identify K5R in retinal Müller cells, ligand binding and competition assays as well as real-time reverse
transcriptional polymerase chain reaction were performed in Müller cells. 125I-K5 showed saturable binding to cultured
Müller cells. The binding can be competed off by an excess amount of unlabeled K5 but not by angiostatin, demonstrating
the specificity of the K5 binding to Müller cells. Consistent with the binding assay, reverse transcriptional polymerase
chain reaction using voltage-dependent anion channel–specific primers detected the K5R mRNA in the Müller cells.
Results: Interestingly, K5R mRNA expression in Müller cells was downregulated by diabetic conditions including hypoxia
and high glucose medium. Incubation with K5 ligand prevented hypoxia-induced downregulation of K5R. Furthermore,
K5R expression was also downregulated in the retina of the oxygen-induced retinopathy model, a model of ischemia-
induced retinal neovascularization. In a type 1 diabetic rat model, K5R expression in the retina was significantly suppressed
in rats that had diabetes for 5 and 8 weeks.
Conclusions: These results suggest that K5R is expressed in retinal Müller cells, which may mediate the inhibitory effect
of K5 on VEGF expression. In diabetes conditions, K5R expression levels are decreased in the retina, which could
contribute to the VEGF overexpression in diabetic retinopathy. These findings suggest that the decreased levels of K5R
may also play a pathogenic role in diabetic retinopathy.
Proliferative diabetic retinopathy (PDR) is characterized
by retinal neovascularization (NV), a major cause of blindness
[1].  Several  endogenous  angiogenic  inhibitors  as  well  as
proangiogenic factors exist in ocular tissues such as the retina
and  vitreous  [2,3].  Endogenous  angiogenic  inhibitors  and
proangiogenic factors are in a delicate balance that regulates
angiogenesis. Under certain pathological conditions such as
PDR, endogenous angiogenic inhibitors have been found to
decrease while the proangiogenic factors increase in the retina
and vitreous, leading to a disturbed balance in angiogenic
control and consequently retinal NV [4–6].
Plasminogen kringle 5 (K5), a proteolytic fragment of
plasminogen, is a potent angiogenic inhibitor [7]. Previous
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studies have shown that K5 inhibits endothelial cell (EC)
proliferation and migration and induces EC apoptosis [7,8].
Intravitreal injection of K5 inhibited retinal NV and reduced
retinal vascular leakage in diabetic retinopathy (DR) models
[9]. Furthermore, K5 and its deletion fragment also displayed
inhibitory effects on tumor growth via blocking angiogenesis
[10,11]. Adeno-associated virus-mediated delivery of K5 was
found to inhibit growth of ovarian cancer and tumor NV
[12]. A recent study reported that nanoparticle-mediated K5
gene  delivery  had  sustained  inhibitory  effects  on  retinal
vascular leakage in diabetic rats and ischemia-induced retinal
NV  [13].  Therefore,  K5  is  believed  to  be  a  promising
therapeutic peptide for treating DR as well as solid tumor
[13]. Our previous studies showed that K5 attenuates hypoxia-
induced  vascular  endothelial  growth  factor  (VEGF)
overexpression in vascular cells [14]. However, the molecular
mechanism  for  K5′s  antiangiogenic  effects  has  not  been
elucidated.
Molecular Vision 2012; 18:330-336 <http://www.molvis.org/molvis/v18/a36>
Received 15 September 2011 | Accepted 1 February 2012 | Published 4 February 2012
© 2012 Molecular Vision
330Researchers reported previously that voltage-dependent
anion channels (VDACs) are expressed on the cell surface of
EC [15]. Furthermore, K5 has been shown to bind to VDAC
with high specificity and affinity in EC, correlating with K5′s
antiproliferative activities in cultured EC. The binding of K5
to EC can be blocked by antibodies specific for VDAC. Based
on  these  findings,  VDAC  has  been  proposed  as  the  K5
receptor  (K5R),  mediating  its  antiangiogenic  effects  [15].
However, the role of K5R in angiogenic disorders and PDR
has not been established. The cellular localization of K5R in
the retina has not been defined.
Retinal  Müller  cells  are  the  major  producer  of
proangiogenic factors such as VEGF in DR and play a key
role in retinal NV [3,16]. Since K5 inhibits VEGF expression
under  hypoxia,  we  hypothesize  that  K5  directly  inhibits
angiogenic  factor  production  from  retinal  Müller  cells  in
diabetic  conditions.  The  present  study  identified  K5R  in
retinal Müller cells and determined the expression levels of
K5R under diabetic conditions.
METHODS
Materials  and  cell  line:  Expression  and  purification  of
recombinant  K5  were  performed  as  described  previously
[14]. The K5/pET22 construct was introduced into E. coli
strain  BL-21/DE3  (Novagen,  Madison,  WI).  This  vector
provides a signal peptide that enables the recombinant protein
to enter the periplasmic space. The expression and purification
followed the protocol recommended by Novagen with some
modifications.  Briefly,  expression  was  induced  by  the
addition  of  isopropylthio-β-galactoside  (IPTG)  and
performed  for  10  h  at  25  °C.  Periplasmic  proteins  were
released by digestion with lysozyme and separated from cells
by centrifugation. K5 was purified by passing through the His-
Bind  column  (Novagen).  The  purity  and  identity  of
recombinant K5 was examined by SDS–PAGE and western
blot analysis using an antibody specific to His-tag (Oncogene
Research Products, Cambridge, MA).The rat Müller cell line,
rMC-1, a kind gift from Dr. Vijay Sarthy at Northwestern
University, was cultured in low glucose Dulbecco's Modified
Eagle's Medium (DMEM; Gibco BRL, Gaithersburg, MD)
containing  10%  fetal  bovine  serum  (FBS;  Invitrogen,
Carlsbad, CA) [17]. The cultured cells were exposed to media
containing 1% FBS for 4 h before proteins were added.
Enzyme-linked  immunosorbent  assay  and  western  blot
analysis of vascular endothelial growth factor: Müller cells
were seeded in 100-mm dishes and cultured in a CO2 incubator
to reach 60%–70% confluence. The cells were washed three
times  with  PBS  (pH  7.4,  8g  NaCl,  0.2g  KCl,  3.628  g
Na2HPO4•12H2O, 0.24 g KH2PO4 metered volume to 1,000 ml
with distilled water), and the growth medium replaced with a
serum-free DMEM and exposed to 1% oxygen. K5 was added
to the medium in various concentrations (50, 100, 200, 400,
and 800 nM) and incubated with the cells for 24 h. The cells
cultured under normoxia were used for control. The cells were
harvested, and the protein concentration was measured with
the BioRad protein assay (Bio-Rad, Hercules, CA). Equal
amounts of total cellular protein (35 μg) from each group were
used for western blot analysis using an anti-VEGF antibody
with the ECL Detection System (Amersham International plc,
Piscataway,  NJ).  The  same  membrane  was  stripped  and
reblotted with an antibody specific to β-actin. VEGF secreted
into the culture medium was measured with an enzyme-linked
immunosorbent  assay  (ELISA)  kit  (R&D  Systems,  Inc.,
Minneapolis, MN) specific for VEGF.
Binding of 125I-labeled K5 to Müller cells: K5 was labeled with
125I  using  the  Chloromine  T  125I  Labeling  Kit  (ICN
Pharmaceuticals, Inc. Costa Mesa, CA) following a protocol
recommended by the manufacturer. For the binding assay,
Müller cells were seeded in 12-well plates and cultured until
confluence. Cells were washed, and the culture medium was
replaced with binding buffer (PBS containing 3 mM CaCl2,
1 mM MgCl2, and 5 mg/ml BSA). 125I-K5 was added to various
concentrations (0, 6.25, 12.5, 25, 50, 75, 100, 150, 200, and
250 nM) and incubated with the cells for 1 h with gentle
shaking at 4 °C. The medium was removed, and cells washed
three times with PBS. The cells were then lysed by adding
0.35 ml 10% sodium dodecyl sulfate. The cell lysates were
collected, and the 125I-K5 bound to Müller cells was quantified
with a gamma counter (Perkin Elmer, Watham, MA).
Competition  with  125I-K5  for  binding  to  Müller  cells  by
unlabeled K5 or angiostatin: The cells were incubated with
50 nM 125I-K5 in the presence of increasing concentrations (0,
50, 250, 1,250, and 6,250 nM) of unlabeled K5 or angiostatin
as described above. After washing, the bound  125I-K5 was
quantified.
Streptozotocin-induced diabetes: Brown Norway (BN) rats
were purchased from Harlan (Indianapolis, IN). Care, use, and
treatment of all animals in this study were in strict agreement
with  the  Association  for  Research  in  Vision  and
Ophthalmology  Statement  for  the  Use  of  Animals  in
Ophthalmic and Vision Research. Eight-week-old BN rats
were given a single intravenous injection of STZ (50 mg/kg
in 10 mmol/l of citrate buffer, pH 4.5) after an overnight
fasting. Control rats received injections of citrate buffer alone.
Serum glucose levels were checked 24 h after STZ injection
and every 2 days thereafter, and only the animals with glucose
levels higher than 350 mg/dl were considered diabetic [18,
19].
Oxygen-induced  retinopathy:  Induction  of  retinal
neovascularization was performed as described by Smith et
al. [20], with minor modifications. Briefly, newborn BN rats
at P7 were exposed to hyperoxia (75% O2) for 5 days (P7–12)
and then returned to normoxia (room air) to induce retinal
neovascularization. Control rats were maintained in constant
room air.
Real-time reverse transcription–polymerase chain reaction:
Real-time  reverse  transcription–polymerase  chain  reaction
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primers used for human VDAC1 (5′-AAC ACT CGC TTT
GGA ATA AC-3′ and 5′-AGT CCT AAA CCA AGC TTG
TG-3′)  amplified  a  180-bp  single-band  product.  The  18S
rRNA was amplified using primers (5′-TGC TGC AGT TAA
AAA GCT CGT-3′, and 5′-GGC CTG CTT TGA ACA CTC
TAA-3′) to normalize the K5R mRNA levels.
Statistical  analysis:  The  Student  t  test  was  used  in  all
statistical analyses. A p value of less than 0.05 was considered
statistically significant.
RESULTS
K5  attenuated  the  hypoxia-induced  vascular  endothelial
growth  factor  overexpression  in  cultured  Müller  cells:
Overexpression of VEGF in the retina induced by hypoxia
plays a key role in retinal NV [6]. Since retinal Müller cells
are the major source of VEGF in DR, we determined whether
K5  has  a  direct  inhibitory  effect  on  VEGF  expression  in
Müller cells. The rat Müller cell line, rMC-1, was exposed to
1% oxygen to induce hypoxia. As shown with enzyme-linked
immunosorbent  assay  (ELISA)  specific  for  VEGF,  the
secreted VEGF in the conditioned medium was significantly
induced by hypoxia, and this induction was attenuated by K5
in a concentration-dependent manner (Figure 1A). Western
blot analysis showed that K5 also blocked the increase in
cellular  VEGF  levels  induced  by  hypoxia  in  Müller  cells
(Figure 1B).
Detection of K5R expression in retinal Müller cells: To test
the hypothesis that the effect of K5 in Müller cells is mediated
by a receptor for K5, we used a K5 binding assay. The cultured
rMC-1 cells were incubated with increasing concentrations of
125I-K5. After unbound 125I-K5 was removed by washing, the
cells were lysed, and 125I-K5 bound to the cells were quantified
using  a  gamma  counter,  which  showed  a  concentration-
dependent and saturable binding of  125I-K5 to Müller cells
(Figure 2A). We calculated the Kd as 31 nM, comparable to
that reported by Gonzalez-Gronow et al. [15].
To further demonstrate the specificity of the K5 binding,
the Müller cells were incubated with 50 nM  125I-K5 in the
presence of excess amounts of unlabeled K5 or unlabeled
angiostatin, kringles 1–4 of plasminogen [22]. The results
showed  that  binding  of  125I-K5  on  the  Müller  cells  was
competed off by excess amounts of unlabeled K5 but not by
angiostatin (Figure 2B,C). The unlabeled K5 inhibited the
binding  of  125I-K5  in  a  concentration-dependent  manner,
demonstrating  the  specificity  of  the  binding  of  125I-K5  to
Müller cells (Figure 2B). These results suggest that K5R is
expressed in retinal Müller cells.
K5R  expression  was  downregulated  by  hypoxia  and  high
glucose in Müller cells: Previous studies have shown that the
expression of VEGF is upregulated in retinal Müller cells
[16]. Since K5 inhibits VEGF expression under hypoxia in
Müller  cells,  we  determined  whether  K5R  expression  is
altered under diabetic conditions, which may contribute to the
overexpression of VEGF. We compared expression levels of
the K5R mRNA in the cells exposed to high glucose medium
(25 mM glucose) with those in low glucose medium (5 mM
glucose + 20 mM mannitol control). Real-time RT–PCR using
specific primers for K5R showed that K5R mRNA levels were
significantly decreased by high glucose exposure, compared
to that in the low glucose medium (Figure 3).
Similarly, the cells were exposed to 1% oxygen to induce
hypoxia, and the K5R mRNA was quantified and compared
to that in the normoxia control. Real-time RT–PCR showed
that K5R mRNA levels were also significantly decreased by
hypoxia (Figure 3).
K5 attenuated the downregulation of K5R expression: To
determine the impact of K5 on the expression of K5R, Müller
cells were exposed to hypoxia in the presence of purified
recombinant K5. As shown with real-time RT–PCR, hypoxia
significantly decreased K5R mRNA levels, while adding the
K5 peptide attenuated the hypoxia-induced downregulation of
K5R (Figure 4). This observation suggests that preventing the
Figure 1. K5 inhibited the hypoxia-induced vascular endothelial
growth factor overexpression in cultured Müller cells. rMC-1 cells
were exposed to normoxia (20% oxygen) and hypoxia (1% oxygen)
with different concentrations of K5 for 24 h. A: VEGF secreted to
the conditioned medium was measured using ELISA specific for
VEGF, normalized by total protein concentration and expressed as a
picogram of VEGF per milligram of total protein (mean±SD, n=4).
Values significantly lower than control are indicated (*p<0.05). B:
VEGF levels in cell lysates were measured with western blot analysis
using 50 µg cellular proteins. The membrane was stripped and then
reblotted with an anti-β-actin antibody.
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Figure 2. K5 specifically bound to retinal Müller cells. A: Rat Müller
cells were incubated with increasing concentrations of 125I-labeled
K5 for 1 h followed with thorough washing with PBS. Then 125I-K5
bound to the cells were quantified using a γ-counter (mean±SD, n=3).
The  binding  of  125I-K5  to  Müller  cells  appeared  concentration-
dependent and saturated above 100 nm of K5. B: The cells were
incubated with 50 nM of 125I- K5 and increasing concentrations of
unlabeled K5 at 37 °C for 1 h, washed with PBS, and 125I-K5 on the
cells was quantified by γ-counting (mean±SD, n=3). C: The cells
were incubated with 50 nM of 125I- K5 and increasing concentrations
of unlabeled angiostatin under the same conditions. After thorough
washing, 125I-K5 on the cells were quantified (mean±SD, n=3). The
binding of 125I-K5 to Müller cells was competed off by increasing
concentrations of unlabeled K5 but not by angiostatin.
action.
K5R  expression  was  downregulated  in  the  retina  of  the
oxygen-induced  retinopathy  rat  model:  To  investigate
whether  K5R  is  also  downregulated  in  the  retina  of  DR
models, we employed rats with oxygen-induced retinopathy
(OIR), a commonly accepted model for PDR [20,23]. At age
of P14 and P16, the OIR rats showed significantly decreased
K5R mRNA levels in the retina, compared to those of age-
matched rats at constant normoxia (Figure 5). This finding
suggests that the K5R decline in this model may be another
pathogenic mechanism for retinal NV in OIR rats.
K5R expression is suppressed in the retina of diabetic rats:
K5R expression was also measured in the retina of STZ-
induced diabetic rats, a type 1 diabetes model. Real-time RT–
PCR showed that K5R mRNA levels in the retina declined in
rats that had diabetes for 5 and 8 weeks, compared to that in
the non-diabetic control. The decrease of the K5R mRNA
levels appeared to be dependent on the duration of diabetes
(Figure 6), suggesting that the decrease in K5R may also
contribute to retinal vascular leakage in this model.
DISCUSSION
Previous  studies  have  shown  that  endogenous  angiogenic
inhibitors are downregulated in the vitreous from patients with
DR and in the retina of DR models [4,5]. The decrease of
angiogenic inhibitors and overexpression of proangiogenic
Figure 3. K5R expression was down-regulated by hypoxia and high
glucose.  Müller  cells  were  exposed  to  hypoxia  (1%  oxygen)  or
normoxia (20% oxygen) at 37 °C for 12 h. The cells were cultured
in high glucose (25 mM glucose) and low glucose (5 mM glucose +
20 mM mannitol) media for 24 h. Total RNA was isolated from the
cells and used for real-time RT–PCR of K5R, normalized by the 18s
RNA level and expressed as % of respective control (mean±SD,
n=3).  Values  significantly  lower  than  control  are  indicated
(*p<0.05). Hypoxia and high glucose significantly downregulated
the expression of the K5R mRNA in cultured Müller cells.
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333factors disturb the balance of angiogenesis regulation, leading
to DR [23,24]. The present study showed for the first time that
the  receptor  for  the  angiogenic  inhibitor  K5  is  also
downregulated in the retina of DR models, suggesting that
decreased expression of receptors for angiogenic inhibitors
may weaken the antiangiogenic action and, thus, represents a
new pathogenic mechanism for DR.
Several groups have independently demonstrated that K5
is a potent angiogenic inhibitor, as it inhibits EC proliferation
and  migration  [7,9].  Toward  its  mechanism  of  action,
Gonzalez-Gronow  et  al.  [15]  identified  VDAC1  as  the
receptor for K5, which is expressed on the surface of EC. The
expression of K5R on EC can explain the direct inhibitory
effect of K5 on EC proliferation and migration [15]. Our
previous  studies  have  shown  that  K5  inhibits  VEGF
overexpression  in  the  retina  of  DR  models  [14].  Retinal
Müller cells play a key role in DR, as they are the major source
of inflammatory and angiogenic factors such as VEGF [16,
25].  Our  results  showed  that  K5  directly  inhibits  VEGF
expression in cultured Müller cells. The mechanism for the
direct effect of K5 on VEGF expression in Müller cells is
unclear. To investigate whether the receptor mediates the K5
effects on Müller cells, we performed a 125I-K5 binding assay.
The assay demonstrated that K5 has saturable and specific
Figure 4. K5 induced K5R expression in Müller cells. Müller cells
were exposed to 1% oxygen in the presence of 200 nM K5 at 37 °C
for 12 h. Total RNA was isolated from the treated cells. The K5R
mRNA was quantified with real-time RT–PCR and normalized by
18s RNA levels (mean±SD, n=3). The copies of K5R mRNA in
hypoxia group were significantly lower than that in normoxia group
(*p<0.05). K5 prevented the hypoxia-induced downregulation of
K5R mRNA expression in cultured Müller cells.
binding  to  cultured  Müller  cells.  The  binding  of  K5  is
reversible and can be competed off by excess amounts of
unlabeled K5. RT–PCR using K5R-specific primers detected
K5R mRNA in cultured Müller cells. These results suggest
that K5R is expressed in Müller cells. Interestingly, the K5
binding to K5R is not competed off by angiostatin, kringles
1–4 of plasminogen, suggesting that K5R is specific for K5
and not the receptor for plasminogen or for kringles 1–4.
Expression of K5R in Müller cells could explain the direct
effect of K5 on Müller cells in downregulation of VEGF
expression.
To study whether K5R expression is altered in retinal
Müller cells under diabetic conditions, we exposed the cells
to hypoxia and high glucose medium, as hypoxia and high
glucose  are  the  major  causative  factors  for  retinal
inflammation and NV in DR, as both have been shown to
induce  expression  of  proangiogenic  and  proinflammatory
factors [20]. Our results showed that hypoxia and high glucose
concentration downregulate K5R expression. The weakened
effect of K5 due to the decrease in its receptor in diabetic
conditions may contribute to the overexpression of VEGF in
Müller cells under diabetic conditions.
In this study, rMC-1 was used as an in vitro model to study
the expression of K5R. rMC-1 is a widely used Müller cell
Figure 5. K5R expression was down-regulated in the retina of the
oxygen-induced retinopathy rat model. Rats were exposed to 75%
oxygen from P7 to P12 of age and then returned to room air at P12.
Total RNA was isolated from the retina of the OIR rats at P14 and
P16. mRNA levels of K5R were quantified with real-time RT–PCR
and normalized with 18s RNA levels and expressed as % of that in
age-matched  normal  rats  (mean±SD,  n=3).  Values  significantly
lower than control are indicated (*p<0.05). K5R mRNA levels were
significantly decreased in the retina of the OIR models, compared to
that in normal rats.
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334line,  since  this  line  is  derived  from  rat  Müller  cells  and
expresses Müller cell markers [26,27]. Using the cloned cell
line excludes potential confusion from contamination of other
cell  types  in  primary  Müller  cell  culture.  However,  the
changes  in  K5R  observed  in  this  cell  line  remain  to  be
confirmed in Müller cells in the retina in the future.
STZ-induced diabetes is a commonly used model for non-
proliferative DR, as this model develops retinal inflammation
and  vascular  leakage  but  not  NV  [18].  The  OIR  model
develops preretinal NV induced by ischemia [20]. Although
the OIR model is not a diabetic model, this model is commonly
used as a model for PDR, as the pathological changes and
pathogenic mechanism are similar to PDR [20]. Our in vivo
results showed that K5R levels in the retina decreased in both
models. Since K5 has anti-inflammatory, antipermeability,
and  antiangiogenic  activities,  the  decreased  K5R  may
contribute to retinal vascular leakage and NV in these models.
The decreased K5R may represent a new mechanism leading
to the weakened antiangiogenic actions of the endogenous
angiogenic  inhibitor  and  disturbing  the  balance  between
proangiogenic  and  antiangiogenic  systems.  Therefore,
upregulation  of  K5R  may  become  a  new,  promising
therapeutic strategy for DR.
Figure 6. K5R expression is suppressed in the retina of diabetic rats.
Diabetes was induced in adult rats with an injection of STZ and
monitored by blood glucose levels. The rats with blood glucose levels
higher than 350 mg/dl were used as diabetic rats. Retinas were
isolated from diabetic rats at 2, 5, and 8 weeks after the STZ injection.
Retinal mRNA levels of K5R were quantified with real-time RT–
PCR and normalized by the 18s RNA level. The normalized K5R
mRNA levels were expressed as % of that in non-diabetic control
(mean±SD,  n=3).  Values  significantly  lower  than  control  are
indicated  (*p<0.05).  Diabetic  rats  showed  significantly  reduced
K5R mRNA levels in the retina, compared to non-diabetic rats.
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